Systemic effects of inhaled corticosteroids

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 1, 2012, Pages 85-89

  Ernst, Pierre ^a   Suissa, Samy ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

adverse effects; asthma therapy; inhaled corticosteroids

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; PLACEBO; SALMETEROL;

ADRENAL FUNCTION; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; GLAUCOMA; HUMAN; INFECTION RISK; LOW DRUG DOSE; PNEUMONIA; PREECLAMPSIA; PREGNANCY; PROGNOSIS; REVIEW; TUBERCULOSIS;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; DIABETES MELLITUS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLAUCOMA; HUMANS; MALE; PNEUMONIA; PREGNANCY; PREGNANCY COMPLICATIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TUBERCULOSIS;

EID: 83155192029     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834dc51a     Document Type: Review

References (36)

1. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001; 107:937-944. (Pubitemid 32523331)
2. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004; 59:16-20. (Pubitemid 38067966)
3. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-955. (Pubitemid 29222495)
4. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a populationbased study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003; 111:736-742. (Pubitemid 36470242)
5. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 50 monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18:328-336. (Pubitemid 40804531)
6. Agertoft L, Pedersen S. Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate. Pediatr Allergy Immunol 2010; 21:e199-e205.
7. Boulet LP, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007; 101:1677-1686. (Pubitemid 46930712)
8. Sagir A, Schmitt M, Dilger K, Haussinger D. Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. Digestion 2003; 68:41-48. (Pubitemid 37256045)
9. Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes. Int J Mol Med 1999; 3:227-238. [review].
10. Zhou S, Yung CS, Cher GB, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44:279-304. (Pubitemid 40477790)
11. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:760-765. (Pubitemid 39298991)
12. Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 2004; 5:235-243. (Pubitemid 38735778)
13. Johnson SR, Marion AA, Vrchoticky T, et al. Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone. J Pediatr 2006; 148:386-388.
14. Samaras K, Pett S, Gowers A, et al. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virusinfected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394-4398. (Pubitemid 41058226)
15. Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 1989; 87:76S-81S. (Pubitemid 20005151)
16. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789. (Pubitemid 46294610)
17. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176:162-166. (Pubitemid 47057852)
18. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:2407-2416.
19. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374:712-719.
20. Crim C. Clinical practice guidelines vs actual clinical practice: the asthma paradigm. Chest 2000; 118 (2 Suppl.):62S-64S. (Pubitemid 30637781)
21. Malo de MR, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010; 36:751-757.
22. Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011; 38:36-41.
23. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007; 176:454-459. (Pubitemid 47358099)
24. O'Byrne PM, Pedersen S, Carlsson LG, et al. Risks of pneumonia in asthmatic patients taking inhaled corticosteroids. Am J Respir Crit Care Med 2011; 183:589-595.
25. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011; 183:675-678.
26. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol 2002; 54:59-64. (Pubitemid 36124755)
27. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123:1001-1006.
28. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277:722-727. (Pubitemid 27106224)
29. Gonzalez AV, Li G, Suissa S, Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm Pharmacol Ther 2010; 23:65-70.
30. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280:539-543. (Pubitemid 28377673)
31. Ernst P, Baltzan M, Deschenes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27:1168-1174. (Pubitemid 44914300)
32. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998; 158:1091-1095. (Pubitemid 28489006)
33. Schatz M, Leibman C. Inhaled corticosteroid use and outcomes in pregnancy. Ann Allergy Asthma Immunol 2005; 95:234-238. (Pubitemid 41376792)
34. Blais L, Beauchesne MF, Lemiere C, Elftouh N. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol 2009; 124:1229-1234.
35. Blais L, BeauchesneMF, Rey E, et al. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax 2007; 62:320-328. (Pubitemid 46580575)
36. Hodyl NA, Stark MJ, Osei-Kumah A, et al. Fetal glucocorticoid-regulated pathways are not affected by inhaled corticosteroid use for asthma during pregnancy. Am J Respir Crit Care Med 2011; 183:716-722.